血漿擴張劑市場－全球產業規模、佔有率、趨勢、機會、預測：按產品類型、最終用戶、地區和競爭格局分類，2021-2031年

全球血漿膨鬆劑市場預計將從 2025 年的 82.5 億美元成長到 2031 年的 169.1 億美元，複合年成長率為 12.71%。

這些由晶體液和膠體液組成的特殊靜脈輸液，對於恢復創傷、低血容性休克或燒傷患者的循環血容量和維持滲透壓至關重要。推動這一市場發展的主要因素是急診醫學中液體復甦的迫切性，以及全球範圍內需要精確血流動力學穩定的大型外科手術數量不斷增加。近期的手術數據也印證了這個趨勢。根據國際美容整形外科學會（ISAPS）的數據，到2025年，全球整體將進行超過1740萬例手術，比前一年增加，這凸顯了對有效的手術全期血容量補充療法的持續需求。

然而，某些合成膠體可能產生的不良生理反應引發的安全性擔憂嚴重阻礙了市場成長。監管機構已發布警告和限制性指南，指出羥乙基澱粉與凝血障礙和腎功能障礙等風險有關。這些臨床風險促使醫療機構採取謹慎的態度，通常以人體血清蛋白或晶體溶液取代合成產品。這種監管措施，加上這些產品所需的嚴格藥物警戒，對合成血漿膨鬆劑市場的更廣泛應用和擴張構成了重大障礙。

市場促進因素

交通事故和創傷事件的日益增加是全球血漿膨鬆劑市場成長的主要推動因素。在嚴重身體創傷和高衝擊力碰撞事故中，必須立即進行液體復甦，以控制低血容性休克並有效恢復血管內液體容量。在這些緊急情況下，血漿膨鬆劑對於維持組織灌注和血流動力學穩定至關重要，直到患者病情穩定或獲得血液製品為止。近期事故數據也印證了這項迫切的臨床需求。根據美國國家公路交通安全管理局 (NHTSA) 於 2024 年 4 月發布的《2023 年機動車死亡人數早期預測》，美國預計將有約 40,990 人死於機動車事故，這凸顯了創傷相關液體復甦治療的持續需求。

同時，慢性心血管疾病盛行率的上升顯著增加了對特殊液體復甦療法的需求。心臟功能受損的患者通常需要使用合成血管擴張劑和人體血清蛋白進行精細的液體管理，以維持滲透壓，避免循環系統負荷過重，尤其是在接受複雜手術時。這些疾病的負擔日益加重，使得頻繁的醫療介入和手術全期支持變得至關重要。根據美國心臟協會 (AHA) 於 2024 年 1 月發布的《2024 年心臟病和中風統計數據》，約 48.6% 的美國成年人患有某種形式的心血管疾病。如此高的盛行率推動了外科病房對血漿製品的需求，並促進了主要行業參與者的財務成長。例如，CSL 有限公司報告稱，其 2024 年的總收入為 148 億美元，這反映了該公司在白蛋白和重症監護領域的強勁表現。

市場挑戰

全球血漿膨鬆劑市場成長的主要障礙在於人們對合成膠體（尤其是羥乙基澱粉）有害生理效應的嚴重安全性疑慮。監管機構已確認這些產品有嚴重的臨床風險，例如凝血障礙和腎功能障礙。因此，監管機構發布了嚴格的指南和黑框警告，要求醫療服務提供者在開立此類溶液時必須謹慎。由於臨床選擇轉向晶體溶液和人體血清蛋白，這種監管壓力正在阻礙市場成長，降低了高利潤合成擴容劑在重症監護領域的商業性應用。

這些安全法規的影響極為嚴重，尤其考慮到目前這些產品在燒傷治療等禁忌症領域擁有龐大的患者族群。根據美國燒傷協會統計，2024年全美每年因燒傷入院的患者人數將達29,165人。儘管這部分患者族群需要大量的液體復甦，但由於腎毒性風險，燒傷治療中禁用合成膠體製劑實際上將這部分需求排除在了目標市場之外。這個關鍵患者族群的缺席直接限制了合成血漿膨鬆劑產業的獲利能力和市場擴張。

市場趨勢

攜帶式和可儲存型軍用醫療製劑的創新正在改變市場格局，有效解決了傳統冷凍血漿在後勤方面的難題。標準血漿需要嚴格的低溫運輸管理，難以在戰場等需要即時進行液體復甦的環境中部署。因此，製造商正在加速開發噴霧乾燥和冷凍乾燥產品，以便在傷患現場快速復溶，並幾乎完全消除冷藏需求。近期取得的臨床里程碑清晰地證明了這項技術進步。 2025年8月，Veliko Medical宣布其FrontlineODP噴霧乾燥血漿系統“已達到關鍵里程碑”，成功完成了首個人體I期臨床試驗，證明了其在嚴苛的軍事環境中的安全性。

此外，隨著血漿製品生產商優先考慮原料自給自足，血漿採集網路的策略性垂直整合以確保供應已成為決定性趨勢。各公司正在最佳化捐血中心的運營，並引入新技術以提高血漿產量，從而確保高需求衍生產品的血漿穩定供應。這種對供應鏈管理的重視，透過緩解供不應求和穩定生產成本，直接支持了業務擴張。根據 Griffols 於 2025 年 2 月發布的《2024 會計年度全年財務業績報告》，該公司生物製藥部門在不計外匯波動影響的情況下實現了 11.3% 的銷售額成長。這項業績歸功於全球血漿供應系統的改進以及每公升血漿成本的成功降低。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球血漿擴張器市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品種類（聚葡萄糖、羥乙基澱粉、人體血清蛋白、聚乙二醇化血清白蛋白、聚乙烯吡咯烷酮（PVP）、明膠）
  • 依最終用戶分類（網路藥局、零售藥局、醫院藥局）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美血漿擴張器市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲血漿擴張劑市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區血漿擴張劑市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲血漿擴張劑市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲血漿擴張劑市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球血漿擴張器市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Baxter International Inc.
• Fresenius SE & Co. KGaA
• CSL Limited
• Grifols, SA
• B. Braun Melsungen AG
• Hikma Pharmaceuticals PLC
• Octapharma AG
• Kedrion SpA
• Shanghai RAAS Blood Products Co., Ltd.
• Terumo Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Plasma Expander Market is projected to escalate from USD 8.25 Billion in 2025 to USD 16.91 Billion by 2031, reflecting a compound annual growth rate of 12.71%. These specialized intravenous solutions, consisting of crystalloids and colloids, are essential for restoring circulating blood volume and maintaining oncotic pressure in patients experiencing trauma, hypovolemic shock, or burns. The market is primarily driven by the urgent need for fluid resuscitation in emergency medicine and the growing volume of major surgical interventions globally that demand precise hemodynamic stabilization. This trend is supported by recent procedural data; according to the International Society of Aesthetic Plastic Surgery, in 2025, reports indicated that over 17.4 million surgical procedures were conducted worldwide in the previous year, highlighting a continuous need for effective perioperative volume replacement therapies.

However, market growth faces significant obstacles due to safety concerns regarding the adverse physiological effects of specific synthetic colloids. Regulatory authorities have issued warnings and restrictive guidelines linking hydroxyethyl starches to risks such as coagulopathy and renal impairment. These clinical risks have prompted healthcare providers to adopt a cautious approach, often substituting synthetic options with human albumin or crystalloids. This regulatory scrutiny, combined with the rigorous pharmacovigilance required for these products, acts as a major barrier to the broader adoption and expansion of the synthetic plasma expander segment.

Market Driver

The increasing incidence of road accidents and traumatic injuries serves as a primary catalyst for the Global Plasma Expander Market's growth. Severe physical trauma and high-impact collisions require immediate fluid resuscitation to manage hypovolemic shock and effectively restore intravascular volume. In these emergency situations, plasma expanders are crucial for maintaining tissue perfusion and hemodynamic stability until the patient stabilizes or blood products become available. This urgent clinical necessity is underscored by recent accident data; according to the National Highway Traffic Safety Administration, April 2024, in the 'Early Estimate of Motor Vehicle Traffic Fatalities in 2023', approximately 40,990 individuals died in motor vehicle traffic crashes in the United States, emphasizing the persistent demand for trauma-related volume replacement therapies.

Simultaneously, the rising prevalence of chronic cardiovascular disorders is significantly boosting the demand for specialized volume replacement therapies. Patients with compromised cardiac function often undergo complex surgeries or require meticulous fluid management, utilizing synthetic expanders or human albumin to maintain oncotic pressure without overloading the circulatory system. The burden of these conditions is growing, necessitating frequent medical interventions and perioperative support. According to the American Heart Association, January 2024, in the 'Heart Disease and Stroke Statistics 2024 Update', nearly 48.6 percent of U.S. adults have some form of cardiovascular disease. This prevalence drives the consumption of plasma derivatives in surgical wards, contributing to the financial growth of major industry players; for instance, according to CSL Limited, in 2024, the company reported total revenue of 14.8 billion USD, reflecting strong performance in their albumin and critical care portfolios.

Market Challenge

A primary obstacle hindering the growth of the Global Plasma Expander Market is the significant safety concern regarding the adverse physiological effects of synthetic colloids, particularly hydroxyethyl starches. Regulatory bodies have identified serious clinical risks associated with these products, including coagulopathy and renal impairment. Consequently, strict guidelines and black box warnings have been issued, compelling healthcare providers to exercise caution when prescribing these solutions. This regulatory pressure impedes market growth by driving a shift in clinical preference towards crystalloids or human albumin, thereby reducing the commercial adoption of higher-margin synthetic expanders in critical care settings.

The impact of these safety restrictions is especially detrimental given the large volume of patients in segments where these products are now contraindicated, such as burn management. According to the American Burn Association, in 2024, the organization reported that annual national hospital burn admissions reached 29,165. Although this patient population represents a critical demographic requiring extensive fluid resuscitation, the prohibition of synthetic colloids for burn injuries due to kidney toxicity risks effectively eliminates this demand from the addressable market. This exclusion of a key patient segment directly limits the revenue potential and expansion of the synthetic plasma expander sector.

Market Trends

Innovation in portable and shelf-stable formulations for military combat care is transforming the market by addressing the logistical challenges of traditional frozen plasma. Standard plasma requires strict cold-chain maintenance, making deployment difficult in battlefield environments where immediate fluid resuscitation is vital. Manufacturers are therefore accelerating the development of spray-dried and freeze-dried products that allow for rapid reconstitution at the point of injury, effectively bypassing the need for refrigeration. This technological progress is highlighted by recent clinical milestones; according to Velico Medical, August 2025, in the 'FrontlineODP Spray Dried Plasma Achieves Key Milestone' announcement, the company successfully completed its first-in-human Phase I clinical trial for a spray-dried plasma system, demonstrating safety for deployment in austere military settings.

Furthermore, the strategic vertical integration of plasma collection networks to secure supply has become a decisive trend as fractionators prioritize raw material self-sufficiency. Companies are optimizing donor center operations and implementing technologies to enhance yield, ensuring a consistent stream of plasma for high-demand derivatives. This focus on supply chain control mitigates shortages and directly supports commercial expansion by stabilizing production costs. According to Grifols, February 2025, in the 'Full Year 2024 Results' report, the company's Biopharma division achieved a revenue growth of 11.3 percent at constant currency, a performance attributed to the successful execution of plasma supply improvements and cost-per-liter reductions across its global network.

Key Market Players

• Baxter International Inc.
• Fresenius SE & Co. KGaA
• CSL Limited
• Grifols, S.A.
• B. Braun Melsungen AG
• Hikma Pharmaceuticals PLC
• Octapharma AG
• Kedrion S.p.A.
• Shanghai RAAS Blood Products Co., Ltd.
• Terumo Corporation

Report Scope

In this report, the Global Plasma Expander Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Plasma Expander Market, By Product Type

• Dextran
• Hydroxyethyl Starch
• Human Albumin
• PEGylated Albumin
• Polyvinylpyrrolidone (PVP)
• Gelatin

Plasma Expander Market, By End User

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

Plasma Expander Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Plasma Expander Market.

Available Customizations:

Global Plasma Expander Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plasma Expander Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Dextran, Hydroxyethyl Starch, Human Albumin, PEGylated Albumin, Polyvinylpyrrolidone (PVP), Gelatin)
  • 5.2.2. By End User (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Plasma Expander Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Plasma Expander Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Plasma Expander Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Plasma Expander Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By End User

7. Europe Plasma Expander Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Plasma Expander Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By End User
  • 7.3.2. France Plasma Expander Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Plasma Expander Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Plasma Expander Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Plasma Expander Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By End User

8. Asia Pacific Plasma Expander Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Plasma Expander Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Plasma Expander Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Plasma Expander Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Plasma Expander Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Plasma Expander Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By End User

9. Middle East & Africa Plasma Expander Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Plasma Expander Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By End User
  • 9.3.2. UAE Plasma Expander Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By End User
  • 9.3.3. South Africa Plasma Expander Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By End User

10. South America Plasma Expander Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Plasma Expander Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Colombia Plasma Expander Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By End User
  • 10.3.3. Argentina Plasma Expander Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Plasma Expander Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Baxter International Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Fresenius SE & Co. KGaA
• 15.3. CSL Limited
• 15.4. Grifols, S.A.
• 15.5. B. Braun Melsungen AG
• 15.6. Hikma Pharmaceuticals PLC
• 15.7. Octapharma AG
• 15.8. Kedrion S.p.A.
• 15.9. Shanghai RAAS Blood Products Co., Ltd.
• 15.10. Terumo Corporation

16. Strategic Recommendations

17. About Us & Disclaimer